Nelarabine

FDA Approved: * November 17, 2021
Pharm Company: * ZYDUS PHARMS
Category: Cancer

Nelarabine, sold under the brand names Arranon (US) and Atriance (EU), is a chemotherapy medication used for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). Nelarabine is a prodrug of arabinosylguanine nucleotide triphosphate (araGTP), a type of purine nucleoside analog, which causes inhibition of DNA synthesis and cytotoxicity.[3] Pre-clinical studies suggest that T-cells are particularly sensitive to nelarabine. In Oc... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Nelarabine 5 mg/ml Intravenous Injection
NDC: 14789-114
Labeler:
Nexus Pharmaceuticals LLC
Nelarabine 5 mg/ml Intravenous Injection
NDC: 43598-142
Labeler:
Dr. Reddy's Laboratories, Inc.
Nelarabine 5 mg/ml Intravenous Injection
NDC: 68083-233
Labeler:
Gland Pharma Limited
Nelarabine 5 mg/ml Intravenous Injection
NDC: 70121-1743
Labeler:
Amneal Pharmaceuticals LLC
Nelarabine 5 mg/ml Intravenous Injection
NDC: 70710-1726
Labeler:
Zydus Pharmaceuticals (Usa) Inc.
Nelarabine 5 mg/ml Intravenous Injection
NDC: 70710-1839
Labeler:
Zydus Pharmaceuticals USA Inc.
Nelarabine 5 mg/ml Intravenous Injection
NDC: 70771-1685
Labeler:
Cadila Healthcare Limited
Nelarabine 5 mg/ml Intravenous Injection
NDC: 71288-165
Labeler:
Meitheal Pharmaceuticals Inc
Nelarabine 250 mg/ml Intravenous Injection
NDC: 80978-111
Labeler:
Aqvida Gmbh
Nelarabine 5 mg/ml Intravenous Injection
NDC: 81927-111
Labeler:
Shorla Oncology Inc.

Related Brands

Drugs with the same active ingredients